Aclidinium

Name: Aclidinium

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Pharmacologic Category

  • Anticholinergic Agent
  • Anticholinergic Agent, Long-Acting

Dosing Renal Impairment

No dosage adjustment necessary.

Monitoring Parameters

FEV1, peak flow (or other pulmonary function studies)

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience headache, pharyngitis, or rhinitis. Have patient report immediately to prescriber vision changes, blurred vision, eye pain, severe eye irritation, visual halos or bright colors around lights, urinary retention, painful urination, polyuria, or signs of breathing problems (shortness of breath, wheezing, coughing, or breathing gets worse) (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.

Warnings

Contraindications

Hypersensitivity to drug or formulation components or severe hypersensitivity to milk proteins

Cautions

Not for acute episodes of bronchospasm (ie, not for rescue therapy)

May cause paradoxical bronchospasm; if this occurs, discontinue and consider other treatments

Worsening of narrow-angle glaucoma may occur; use with caution in patients with narrow-angle glaucoma; instruct patients to consult a physician immediately if it occurs

Worsening of urinary retention may occur (eg, prostatic hyperplasia, bladder-neck obstruction); use with caution in patients with prostatic hyperplasia or bladder-neck obstruction; instruct patients to consult a physician immediately if it occurs

Immediate hypersensitivity reactions, including angioedema, bronchospasm, or anaphylaxis, may occur after administration; if hypersensitivity occurs, discontinue immediately and consider alternate treatment

Coadministration with other anticholinergics may increase risk for adverse effects

Patient Handout

Print without Office InfoPrint with Office Info

Usual Adult Dose for Chronic Obstructive Pulmonary Disease - Maintenance

400 mcg (1 inhalation) orally twice a day

Use: Long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

Renal Dose Adjustments

No adjustment recommended.

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Aclidinium Levels and Effects while Breastfeeding

Summary of Use during Lactation

Although no published data exist on the use of aclidinium during breastfeeding, it produces low maternal serum levels because of rapid hydrolysis to inactive metabolites. The risk to the breastfed infant of maternal aclidinium inhalation is small.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Tiotropium, Umeclidinium

References

Administrative Information

LactMed Record Number

1009

Last Revision Date

20150310

Disclaimer

Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

(web3)